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The breast-ovarian cancer susceptibility genes BRCA1 and BRCA2
were isolated in 1994 (Miki et al, 1994) and 1995 (Wooster et al,
1995) respectively. Since then, over thirty studies have investi-
gated the frequency of mutations in these genes in high-risk breast
and breast-ovarian cancer families (Gayther et al, 1998). Estimates
of the proportion of families due to BRCA1 and BRCA2 have
ranged from 6–79%. The probability of a mutation being identified
increases with the number of ovarian cancers and breast cancers in
the family, and with lower average age-at-diagnosis of breast
cancer in the family (Couch et al, 1997; Ford et al, 1998). High-
risk families have also been used to estimate the cumulative risks
(penetrance) of breast and ovarian cancer in mutation carriers. For
breast cancer, estimates of penetrance by age 70 in BRCA1 and
BRCA2 mutation carriers have ranged from 50–85% (Easton et al,
1995; 1997; Ford et al, 1994). For ovarian cancer penetrance by
age 70 has been estimated to be 62–66% for BRCA1 (Ford et al,
1994; Easton et al, 1997; Antoniou et al, 1999), but about half this
for BRCA2 (Ford et al, 1998; Antoniou et al, 1999). Because these
data are from high-risk families the results may not apply to all
carriers of BRCA1 or BRCA2 mutations.
Mutation analysis of BRCA1 and BRCA2 is laborious because of
the large size of the genes and the diversity of mutations. However,
several population isolates have a restricted number of founding
mutations and so are more amenable to population-based studies
of these genes. One per cent of the Ashkenazi Jewish population
carry the mutation BRCA1 185delAG (Struewing et al, 1995) and
1.2% carry the BRCA2 6174delT mutation. These two mutations
account for 20% and 8%, respectively, of early-onset breast cancer
in this population (Neuhausen et al, 1996; Offit et al, 1996). In
Iceland, a single mutation in BRCA2 (999del5) is found in 24%
of women diagnosed before age 40, with little contribution 
from  BRCA1 (Johannesdottir et al, 1996; Thorlacius et al, 1997).
Penetrance estimates from population-based studies in these popu-
lations have generally been lower than those derived from the
high-risk families (Ford et al, 1994; Easton et al, 1995; 1997;
Antoniou et al, 1999). By the age of 70, carriers of the common
Ashkenazi mutations were estimated to have a breast cancer risk
of 56% and a 16% risk of ovarian cancer (Struewing et al, 1997)
and carriers of the Icelandic mutation in BRCA2 had a breast
cancer risk of 38% (Thorlacius et al, 1998). These prevalence
estimates (and perhaps also the penetrance estimates) cannot be
extrapolated to a large outbred population such as the UK.
There have now been several estimates of the contribution of
BRCA1 and BRCA2 to breast cancer incidence in different outbred
populations. Two studies from the USA have tested patients under
35 for mutations in BRCA1: Langston et al (1996) found five (one
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Summary Estimates of the contribution of BRCA1 and BRCA2 to breast cancer incidence in outbred populations have been based on
studies that are either small or have selected for cases diagnosed at an early age. Only one of these has reported an estimate of the breast
cancer risk associated with a mutation in these genes, and there is no published ovarian cancer risk estimate derived from a population-based
case series. We screened a population-based series of breast cancer cases diagnosed before the age of 55 for mutations in BRCA1 and
BRCA2. Pedigree information from the mutation carriers was used to estimate penetrance and the proportion of familial risk of breast cancer
due to BRCA1 and BRCA2. We identified eight (0.7%) BRCA1 and 16 (1.3%) BRCA2 mutation carriers in 1220 breast cancer cases (actual
sample size 1435 adjusted for 15% polymerase chain reaction failure rate). Mutation prevalence was substantially higher in cases diagnosed
before 35 years-of-age and with increasing number of relatives affected with breast or ovarian cancer. However, most mutation carriers were
diagnosed in the older age groups, and a minority reported a first-degree relative with breast cancer. Breast cancer penetrance by age 80 was
estimated to be 48% (95% CI 7–82%) for BRCA1 mutation carriers and 74% (7–94%) for BRCA2 mutation carriers. Ovarian cancer
penetrance for BRCA1 and BRCA2 combined was 22% (6–65%) by age 80. 17% of the familial risk of breast cancer was attributable to
BRCA1 and BRCA2. At birth, the estimated prevalence of BRCA1 mutation carriers was 0.07% or 0.09% depending on the penetrance
function used for the calculation. For BRCA2, the birth prevalence estimates were 0.14% and 0.22%. Mutations in the genes BRCA1 and
BRCA2 are rare in the population and account for a small fraction of all breast cancer in the UK. They account for less than one fifth of the
familial risk of breast cancer. Eligibility criteria for BRCA1 and BRCA2 mutation testing based on family history and age of onset will identify
only a small proportion of mutation carriers. © 2000 Cancer Research Campaign
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(BRCA1 5396 + 60ins12)) mutation carriers out of 80 (6.3%) and
Malone et al (1998) 12 out of 193 (6.2%). Hopper et al (1999)
screened BRCA1 in 91 Australian women diagnosed with breast
cancer before the age of 40 and found three mutations (3.8%). The
largest population-based study published to date, carried out in the
UK, tested 619 cases diagnosed under 45 for mutations in BRCA1
and BRCA2. BRCA1 mutations were found in 2.6% of the cases
and 2.3% of the cases carried mutations in BRCA2 (Peto et al,
1999). The only study to include patients older than 44 found
BRCA1 mutations in three of 211 (1.4%) patients aged 20–74
(Newman et al, 1998). No penetrance estimates for mutations in
these populations have been published.
We have screened a population-based series of 1435 cases diag-
nosed with breast cancer before the age of 55 for mutations in
BRCA1 and BRCA2. To our knowledge this is the largest study to
screen the whole of the coding region of both BRCA1 and BRCA2
for mutations yet carried out, and the only population-based study
of patients diagnosed over the age of 45. Pedigree information
from the mutation carriers we identified was used to estimate
penetrance and to estimate the proportion of familial relative risk
of breast cancer due to BRCA1 and BRCA2. We have also used
these data to estimate the prevalence of BRCA1 and BRCA2 muta-
tion carriers at birth.
METHODS
Case collection
The breast cancer case collection covered the region served by the
Anglian Cancer Registry and all women diagnosed with breast
cancer under the age of 55 between 1 January 1991 and 30 June
1996, who were alive at the start of the study on 1 July 1996, were
eligible for inclusion. The study was approved by all the Local
Research Ethics Committees in East Anglia. Patient details were
obtained from the Anglian Cancer Registry, and the patients’
general practitioners and consultants were contacted in order to
obtain permission to contact the patients. Patient contact was
delayed for at least 3 months after the initial diagnosis. Women
taking part in the study were asked to provide a 20 ml blood
sample and to complete a comprehensive epidemiological ques-
tionnaire. This included questions on family history, reproductive
history (menarche, pregnancies, menopause), oral contraceptive
pill and hormone replacement therapy use, past medical history
and previous examination of the breast by mammography. The
family history included details of all first-degree relatives to
include date and place of birth, date of death, and any history of
cancer. Details of any other relatives known by the case to have
had cancer were also ascertained. Cancer diagnoses reported by
the index cases were not independently verified. The Anglian
Cancer Registry actively follows-up all notified cancer cases, and
so we were able to ascertain second cancer diagnoses and vital
status of the index cases at the end of the study.
Mutation detection
Genomic DNA was extracted from blood using standard methods
on an Extragen automated DNA extractor. The entire coding
sequence and intron–exon boundaries of BRCA1 and BRCA2 was
amplified by polymerase chain reaction (PCR) using 67 primer
pairs. The double-stranded DNA fragments were screened for the
presence of mismatched bases by multiplex heteroduplex analysis
(MHA) with a mildly denaturing polyacrylamide gel matrix 
(10% polyacrylamide (99:1 bis-acryloyl piperazine), 10%
ethylene glycol and 15% formamide) (Ganguly et al, 1993). Up to
four fragments from the same patient, each differing in size by
approximately 100 base pairs, were run in one lane of the gel.
Electrophoresis was performed for 14 h at a constant 200 V, with
gels cooled to 10°C, using the Protean II™ vertical slab gel appa-
ratus. All gels were stained with silver nitrate according to stan-
dard protocols. Mutations were confirmed by direct sequencing of
the PCR product in which a heteroduplex analysis variants had
been found.
Statistical analysis
The proportion of cases with mutations in different age groups and
with different categories of family history were estimated directly.
Ninety-five percent confidence intervals were calculated by
standard methods.
Population frequency of BRCA1 and BRCA2 mutations
The frequency of BRCA1 and BRCA2 mutation carriers in the
population was derived from the gene-specific penetrance and the
proportions of cases due to BRCA1 and BRCA2 in different age-
bands. Assuming that gene mutation carriers have mortality from
causes other than breast cancer that are the same as the general
population, the carrier frequency in the population, p, can be
estimated by solving the equation:
observed number of carriers = pSni(fi – fi–1)gi/(f¢i–f¢i–1)g¢i
Where  fi and  f´i denote breast cancer penetrance in mutation
carriers and the general population respectively, at the end of the
ith 5-year age interval, gi and g´i the probability of not developing
ovarian cancer in mutation carriers and the general population, and
ni the number of index cases in the ith age-group in our study. This
calculation was repeated using our penetrance estimates and those
reported by the Breast Cancer Linkage Consortium (BCLC) (Ford
et al, 1998).
Fraction of breast cancer familial relative risk due to BRCA1
and BRCA2
Expected number of breast cancers occurring before age 85 among
first-degree relatives of index cases were calculated from age- and
period-specific incidence rates for England and Wales using the
PERSON-YEARS program (Coleman et al, 1986). Individuals
were followed from 1960 or from date of birth if born after 1960,
and were censored at reported date of diagnosis of cancer, date of
death, or date the family history questionnaire was completed. The
number of breast cancers in excess of those expected in relatives of
mutation carriers was compared to the excess for all relatives, to
give the fraction of breast cancer familial relative risk due to
BRCA1 and  BRCA2.
Breast cancer penetrance estimation
We used the pedigree information for the mutation carriers to esti-
mate the penetrance of BRCA1 and BRCA2 using the program
MENDEL. Since ascertainment was through a single affected
index case, we maximized the conditional likelihood of the pedi-
gree given the phenotypic and genotypic information of the index
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carriers were assumed to develop the disease at population inci-
dence rates. We parameterized the model in terms of log relative
risk for breast and ovarian cancer in mutation carriers compared 
to general population risks. The breast cancer relative risk was
allowed to vary with age using three age-groups, 20–39, 40–59
and 60–79. Ovarian cancer relative risk was kept constant with
age. Cumulative risks and associated 95% confidence intervals
were calculated by the method given in Appendix 1.
RESULTS
BRCA1 and BRCA2 mutation prevalence
Of 2805 women diagnosed with breast cancer under the age of 55
between 1 January 1991 and 30 June 1996, 569 had died and 200
were thought by their general practitioner to be unfit to take part at
the start of the study. Thus there were 2028 women eligible for
inclusion in the study, of whom 1486 (73%) completed a question-
naire and 1435 (71%) provided a blood sample. The entire coding
sequence and intron–exon boundaries of BRCA1 and BRCA2
were screened for mutations by MHA of 67 separate fragments
following amplification of DNA by polymerase chain reaction
(PCR). Not all samples successfully amplified for each fragment;
85% of a total of 96 145 PCR reactions were sufficiently strong to
score on the MHA gels. We therefore adjusted the number of
samples screened by a factor of 0.85 to give an effective sample
size of 1220.
We detected eight BRCA1 mutations and 16 BRCA2 mutations
that were predicted to encode a truncated protein (Table 1). Two of
these were splice-site mutations, BRCA1 5312 + 2delT and BRCA2
295 + 3T>C, which we believe are likely to be disease-associated.
The first of these affected the donor splice-site consensus sequence
and was found in a patient aged 31 with a strong family history, and
has been reported previously on the Breast Information Core data-
base. The second is previously unreported, and though not affecting
the consensus sequence was also found in a young patient with a
positive family history. cDNA from this patient was available to
confirm the effects of this mutation, which results in skipping of
exon 2. The aberrant splicing results in loss of the start of the
normal open-reading frame with a predicted cryptic open-reading
frame start-site in exon 3, which is out of frame and predicted to
result in a protein of only 20 amino acids.
Three cases were found to have an in-frame deletion. The
BRCA1 variant 1224delGAT (D369del) was found in a patient
aged 53 at diagnosis who had no family history of breast or
ovarian cancer and is reported on the BIC database. The deleted
amino acid is conserved in murine Brca1 but does not lie with-
in any known functional domain. 4369delAAG (E1382del) in
BRCA2, has also been reported on the BIC database, and was
found in two patients; one aged 45 with no family history, and the
other a 50-year-old patient who had a paternal aunt diagnosed with
breast cancer aged 39. Again, the deleted amino acid is conserved
in murine Brca2 but does not lie within any known functional
domain. As the functional significance of these variants is un-
certain we have not included them in the analysis.
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Table 1 Details of cases with identified mutation in BRCA1 or BRCA2
Sample Age Mutation Family history of breast or ovarian cancer Family history of
Mother or sistera Other relativeb other cancerb
BRCA1
R0913 32 2774delC Frameshift M Br (35) – –
R1524 45 2379delG Frameshift Nil – –
R2233 52 3596delAAAG Frameshift Nil – –
R1744 43 1436insC Frameshift Nil – FCo(75), PU St(75)
R1482 49 1619delTAAAT Frameshift Nil MA Br(66) –
R1767 44 3874delTGTC Frameshift S Br (46) – –
R1305 44 4158delAG Frameshift Nil PGM Br(67) –
R2038 31 4912 + 2delT Splice site Nil MGA Br (27,34), MGA Br(?), MGGM St(57)
MGA Br(?), M2C Ov(?)
BRCA2
R1133 34 295 + 3A>G Splice site M Br(50) – –
R1125 46 253delC Frameshift Nil PGM Br(80), PA Ov(57), PA –
Br(43, 57)
R1090 48 983delACAG Frameshift S Br(48) PA Br(52), PA Br(44) PU St(53), PU St(57)
R0495 46 1537delAAGA Frameshift Nil – F Pr(41), D Co(2)
R1725 32 1215insA Frameshift Nil – –
R0431 39 2023delTTACT Frameshift Nil PGM Br (70) –
R2119 41 3034delAAAC Frameshift M Br(72) – –
R1112 50 4538delA Frameshift Nil – –
R0739 54 4866delT Frameshift S Br(49), MA Br(?) F Co(68)
R1646 31 5849delTTAA Frameshift Nil – –
R0003 41 6503delTT Frameshift Nil PA Br(38), PA Br(42) –
R1486 36 6503delTT Frameshift Nil PGM Br(46) –
R1612 48 6719delTG Frameshift Nil MA Ov(60) –
R1846 48 9475delA Frameshift M Br(65), S – MGM St(?)
Br (37, 52)
R0531 51 9303ins31 Frameshift M Br (74) – –
R1066 32 9303ins31 Frameshift Unknown – –
a Br = author to supply; b MA = 000; PA = 000; MGM = 000; MGGM = 000; PGM = 000; MGA = 000; MZC = 000; D = 000; F = 000; PU = 000; St = 000; Co =
000We identified 22 missense variants that occurred in up to four
cases, accounting for 31 cases in total. Fifteen of these have been
previously reported on the BIC database (at http://www.
nhgri.nih.gov/Intramural_research/Lab_transfer/Bic/index.html).
The remaining seven are novel variants. Although it is possible
that some of these are disease-causing, there are no adequate
methods to assess their effect on protein function, and so we have
not classified any of them as disease-associated.
The overall mutation prevalence was low, 0.7% for BRCA1 and
1.3% for BRCA2, but was significantly higher in cases diagnosed
under 35 years-of-age (P < 0.001) (Table 2). There was no
apparent difference in the age distribution of cases due to BRCA1
and BRCA2 in our series. These proportions underestimate the true
contribution of BRCA1 and BRCA2 to breast cancer incidence
because a substantial fraction of mutations, for example large
deletions, are missed by screening just the coding sequence. By
comparing the frequency of known mutations in families linked to
BRCA1, the BCLC estimated the sensitivity of MHA and similar
techniques to be 63% (Ford et al, 1998). On this basis, the overall
proportion of breast cancer below age 55 due to BRCA1 and
BRCA2 is estimated to be 1.2% and 2.1% respectively.
One of the patients who was found to have a mutation did not
complete her family history questionnaire. Of the remaining 23
mutation carriers, seven reported no family history of breast or
ovarian cancer. Two of the eight BRCA1 and six of 16 BRCA2
mutation carriers had a mother or sister affected with breast
cancer, and two BRCA1 and five BRCA2 mutation carriers
reported at least one second-degree relative with breast or ovarian
cancer. Only three mutation carriers reported a family history of
ovarian cancer. Table 3 shows the number of women in different
family history categories that were found to have mutations.
One hundred and seventy seven breast cancers were reported in
female first-degree relatives of the index cases, compared to 105.8
expected from age- and period-specific incidence rates. Eight
mothers or sisters of mutation carriers developed breast cancer
compared to 1.47 expected. If these data are adjusted for the effec-
tive sample size of 85% of the total, and for a mutation detection
sensitivity of 63%, 17% of the excess risk to relatives is attribut-
able to BRCA1 and BRCA2 mutations.
We have estimated the proportion of individuals in the general
population who are carriers of mutations in BRCA1 or BRCA2 at
birth. Assuming a mutation detection sensitivity of 63%, the
estimated prevalences of BRCA1 and BRCA2 carriers at birth are
0.09% and 0.22% respectively, using our penetrance estimates (see
below), and 0.07% and 0.14% if the BCLC penetrance function is
used.
Breast cancer risks in BRCA1 and BRCA2 mutation carriers
The maximum likelihood estimates of the parameters for the
breast and ovarian cancer penetrance models are given in Table 4.
The relative risk of breast cancer for BRCA1 mutation carriers
decreased with age, but for BRCA2 mutation carriers the relative
risk for the three age-groups varied little. The breast and ovarian
cancer cumulative risk (penetrance) estimates based on the esti-
mated age-specific relative risks are presented in Table 5. The risk
associated with mutations in BRCA1 was slightly higher than for
BRCA2 up to age 60, and slightly lower thereafter, but these
estimates are based on a small number of families, and there is a
substantial overlap in the associated confidence intervals.
No first-degree relatives of the index cases were reported as
having ovarian cancer, but two of the index cases (one BRCA1 and
one BRCA2) were diagnosed with ovarian cancer after they had
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Table 2 Prevalence of BRCA1 and BRCA2 mutations in breast cancer cases by age
Age group Number BRCA1 BRCA2 Total
n %a n %a n %a
<35 57 2 4.1 (0.5, 14.1) 4 8.3 (2.3, 19.8) 6 12.4 (4.7, 25.0)
35–44 341 3 1.0 (0.2, 3.0) 4 1.4 (0.4, 3.5) 7 2.4 (1.0, 4.9)
45–54 917 3 0.3 (0.1, 1.1) 8 1.0 (0.4, 2.0) 13 1.7 (0.9, 2.8)
Total 1435 8 0.7 (0.3, 1.3) 16 1.3 (0.8, 2.1) 24 2.0 (1.3, 2.9)
a Adjusted for 15% failure rate in DNA amplification by PCR for mutation analysis
Table 3 Prevalence of BRCA1 and BRCA2 mutations in breast cancer cases by family history
Family history of breast or Breast any age 1 breast < 60 years 1 breast < 50 years
ovarian cancers n Mutation (%a) n Mutation (%a) n Mutation (%a)
No more than one second- 1124 11(1)
degree
One first-degree 136 5(4) 111 5(5) 84 2(3)
breast 119 5(5) 94 5(6) 67 2(4)
ovary 17 0 17 0 17 0
Two first-or second-degree 70 3(5) 45 3(8) 34 2(10)
Two first 9 1(13) 7 1(17) 4 1(29)
One first 33 1(4) 22 1(5) 18 1(7)
One or two first 42 2(6) 29 2(8) 22 2(11)
Two second 28 1(4) 16 1(7) 11 1(11)
Three first- or second-degree 6 2(39) 6 2(39) 4 2(59)
Four + relatives 12 1(10) 11 1(11) 9 1(13)
One first- or second-degree ovary 44 2(6)
a Adjusted for 15% PCR failure ratebeen diagnosed with breast cancer. The estimated cumulative risk
of ovarian cancer by age 70 for BRCA1 and BRCA2 combined was
16% (4–52%).
DISCUSSION
Our mutation prevalence estimates show the expected decline with
increasing age, and are broadly in line with estimates from other
population-based studies. We found that 4.1% of cases diagnosed
under 35 years-of-age carried a mutation in BRCA1. This is
comparable with other published estimates from population-based
studies in this age-group – 6.3% (Langston et al, 1996), 6.2%
(Malone et al, 1998) and 3.5% (Peto et al, 1999) cases under 36.
Our estimate of prevalence of BRCA2 mutations in the same age-
group was somewhat higher than those previously reported: 8.3%
compared with 2.4% (Peto et al, 1999) and 2.2% (Krainer et al,
1997), but there is a substantial overlap between the confidence
intervals of these estimates. In cases aged 35–44 we found 
1.0% with BRCA1 mutations and 1.0% with BRCA2 mutations
compared with 1.9% and 2.2% reported by Peto et al (1999). We
believe that our estimate of mutation prevalence in older cases
(aged 45–54) is the only population-based series of breast cancer
cases that has been screened for mutations in both BRCA1 and
BRCA2.
The observed estimates of mutation prevalences are likely to be
underestimates. Firstly, although we have not classified any of the
rare missense variants and in-frame deletions as disease-causing,
this may be incorrect for some of them. In addition, the sensitivity
of the mutation detection technique is incomplete and large
genomic deletions, mutations in the promoter region and an
unknown proportion of single-base substitutions will be missed.
BRCA1 spans approximately 80 kb of genomic DNA in a region
containing an unusually high density of Alu repeats, which may
make it relatively unstable and prone to deletions and rearrange-
ments (Smith et al, 1996). Indeed, 36% of mutations in Dutch
families are due to three different, large genomic deletions in
BRCA1 (Petrij Bosch et al, 1997), and duplication of exon 13 has
been reported in a BCLC family linked to BRCA1. A large deletion
in BRCA2 has also been reported in a Swedish family (Nordling 
et al, 1998). Unfortunately, unless the specific mutation is known,
testing for large genomic alterations is laborious and requires
substantial quantities of DNA, and is not feasible in the context of
a large population-based study. There are, however, estimates of
the sensitivity of techniques such as MHA, and using families
clearly linked to either gene, the sensitivity of standard mutation
detection techniques has been shown to be around 63%. If our data
are adjusted for a mutation sensitivity of 63%, the overall BRCA1
mutation prevalence becomes 1.3% and for BRCA2, 2.1%.
The mutation prevalence estimates may also be biased by pref-
erential survival between cases with mutations and those without.
Several studies have compared survival of BRCA1-associated
breast cancer to that of BRCA1-negative cases with conflicting
results (Ansquer et al, 1998; Verhoog et al, 1998; Watson et al,
1998). However, the pathological features of BRCA1-associated
tumours would predict a poorer survival in this group of patients.
If the survival of BRCA1-associated tumours was half that of
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Table 4 Penetrance model parameter estimates
Mutation Model Parametera Breast cancer Ovarian
loglikelihood cancer
20–39 40–59 50–79 20–79
BRCA1/2 –66.3 Relative risk 26.4 11.8 17.6 15.9
Ln (RR) 3.27 2.47 2.87 2.77
SE Ln (RR) 0.73 0.60 0.76 0.75
BRCA1 –17.1 Relative risk 58.4 14.7 1.00 41.8
Ln (RR) 4.07 2.67 0.00 3.73
SE Ln (RR) 1.10 1.33 0.00 1.25
BRCA2 –47.8 Relative risk 17.2 11.2 22.5 9.9
Ln (RR) 2.84 2.42 3.11 2.29
SE Ln (RR) 1.02 0.68 0.75 1.03
a < n = ; SE = (author to supply)
Table 5 Cumulative breast and ovarian cancer risks (%) in BRCA1 and BRCA2 mutation carriers
Age Gen populationa BRCA1b BRCA2b Allb
Breast cancer
40 0.4 20 (0–50) 6 (0–17) 10 (0–21)
50 1.5 32 (2–62) 18 (2–32) 21 (5–34)
60 3.1 46 (3–82) 31 (3–53) 34 (5–55)
70 5.0 47 (5–82) 56 (5–80) 54 (14–76)
80 7.1 48 (7–82) 74 (7–94) 69 (11–90)
Ovarian cancer
40 0.1 3 (0–30) 1 (0–5) 1 (0–5)
50 0.3 11 (1–74) 3 (0–19) 4 (1–18)
60 0.7 24 (2–96) 6 (1–39) 10 (2–37)
70 1.0 36 (4–99) 10 (1–55) 16 (4–51)
80 1.5 47 (5–100) 14 (2–68) 22 (6–65)
a Based on 1983–87 incidence for England and Wales; b 95% confidence interval in bracketsBRCA1-negative cases, the estimated BRCA1-mutation prevalence
would increase by a factor of 1.3. There are no data on survival of
BRCA2-associated breast cancer, but these tumours tend to have a
histopathology comparable with that of control (Breast Cancer
Linkage Consortium, 1997).
As expected, the proportion of women with a mutation varied
according to family history, the proportion increasing with
increasing number of affected relatives. Several studies have
shown that the probability of finding a mutation in BRCA1 or
BRCA2 in breast cancer families is substantially greater if there is
at least one relative affected with ovarian cancer. Although none of
24 cases with a single first-degree relative affected with ovarian
cancer were found to be mutation carriers, a mutation was found in
three of 55 cases that reported ovarian cancer in at least one
relative.
These findings have important implications for determining
policy for BRCA1 and BRCA2 mutation testing. Eligibility criteria
for testing should take into account their sensitivity and positive
predictive value. In this context, the sensitivity is the proportion of
the cases who are mutation carriers who are identified by the
criteria, and the positive predictive value is the proportion of those
who fulfil the criteria who are found to be mutation carriers. Any
criteria based on family history alone or in combination with age
of onset will have a limited sensitivity because a significant
proportion of the total number of mutation carriers identified
occurs in older cases with little or no family history. For example,
if all women diagnosed with breast cancer under 35 years-of-age
and those with at least two affected relatives on the same side of
the family, one of whom was diagnosed aged less than 50, were
eligible for testing, a mutation in BRCA1 or BRCA2 would be
found in approximately 10% (the positive predictive value). These
criteria would have identified 10 out of the 24 mutation carriers
identified in the ABC study, a sensitivity of 42%. More stringent
criteria will improve the positive predictive value, but at the
expense of sensitivity.
We found that only 17% of the breast cancer familial relative
risk can be accounted for by BRCA1 and BRCA2, which suggests
that there may be other breast cancer susceptibility genes. How-
ever, because the proportion of cases with a mutation increases as
the familial clustering increases, these putative genes are likely to
have a lower penetrance than BRCA1 and BRCA2. This hypothesis
is consistent with the findings of Peto et al (1999) and with a
recent analysis of the BCLC families, which found that only one-
third of site-specific breast cancer families with only four or five
affected members were due to BRCA1 or BRCA2 (Ford et al,
1998). Our estimates of the prevalence of the two genes in the
general population are similar to those published elsewhere (Ford
et al, 1995; Peto et al, 1999).
Although the cumulative breast cancer risk by age 70 was
higher for BRCA2 than for BRCA1, these were not statistically
significantly different. Like other penetrance estimates derived
from population-based studies (Struewing et al, 1997; Thorlacius
et al, 1998; Hopper et al, 1999), breast cancer risks were somewhat
lower than those derived from high-risk families (Ford et al,
1998). Our estimate of ovarian cancer penetrance was also lower
than the estimates derived from high-risk families, and identical to
the only published estimate of ovarian cancer penetrance derived
from a population-based study of breast cancer (Struewing et al,
1997). Other estimates for BRCA1 ovarian cancer penetrance by
age 70 have ranged from 53% using data from ovarian cancer
families (Antoniou et al, 1999) to 63% based on the BCLC fami-
lies (Easton et al, 1995). Antoniou et al (1999) also estimated the
ovarian cancer penetrance by age 70 to be 68% using data from a
population-based study of ovarian cancer. The two published esti-
mates of BRCA2 ovarian cancer penetrance have been lower: 27%
using BCLC families (Ford et al, 1998) and 31% using ovarian
cancer families. The reasons for the differences in ovarian cancer
risks derived from the population-based studies and the high-risk
families are not clear. Site-specific differences in breast and
ovarian cancer risk (allelic heterogeneity) have been described for
mutations in both BRCA1 (Gayther et al, 1995) and BRCA2
(Gayther et al, 1997), but these effects do not seem large enough 
to explain the observed risk differences, and modifying genes
segregating in the high-risk families may also be important.
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APPENDIX 1
Cumulative risk of penetrance and 95% confidence intervals (95% CI) were calculated from the cumulative incidence L(t), where:
where ik = incidence in the kth age-band of length Tk, and bk = ln(RR) in kth age-band.
The cumulative risk F(t) is given by:
F(t) = 1 –exp(–L(t))
with 95% CI = 1 – exp(–L(t) ± 1.96ÖvarL(t)
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n
L(t) = Siktk exp(bk)
k = 1
nn
var L(t) = Si2
kt2
k var(bk) exp(2bk) + 2 S ikijTkTj[ var(bk) var(bj)]1/2 exp(bk) exp(bj)corr(bk, bj)
k = 1 j < k
k = 1